Increased platelet purinergic sensitivity in peripheral arterial disease - A pilot study

Platelets

Volumn 16, Issue 5, 2005, Pages 261-267

  Braun, Oscar Ö ^a   Jagroop, Anita ^b   Wang, Lingwei ^a   Mikhailidis, Dimitri P ^b   Burnstock, Geoffrey ^b   Erlinge, David ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Peripheral arterial disease; Platelets; Purinergic receptors

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; IMIDAPRIL; INDAPAMIDE; MESSENGER RNA; PURINE; PURINE P2X1 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; STROKE; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE SHAPE; THROMBOCYTE VOLUME; WESTERN BLOTTING;

ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BLOTTING, WESTERN; CELL SIZE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PILOT PROJECTS; PLATELET AGGREGATION; PLATELET COUNT; RECEPTORS, PURINERGIC P2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

MOROCCAN PEPPER VIRUS;

EID: 21644490493     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100400020203     Document Type: Article

References (45)

1. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154(3):485-490.
2. Erlinge D. Extracellular ATP: a growth factor for vascular smooth muscle cells. Gen Pharmacol 1998;31(1):1-8.
3. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003;41(4 Suppl. S):7S-14S.
4. Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002;16(2):246-258.
5. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003;9(1):61-67.
6. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res 1996;82(6):523-532.
7. Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg 2003;25(1):16-22.
8. Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol 1994;13(3):202-207.
9. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25(6):1172-1181.
10. Dormandy J, Heeck L, Vig S. Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease. Semin Vasc Surg 1999;12(2):118-122.
11. Wang L, Ostberg O, Wihlborg A-K, Brogren H, Jern S, Erlinge D. Quantification of ADP and ATP receptor expression in human platelets. J Thromb Haemost 2003;1:328-334.
12. Kunapuli SP, Dorsam RT, Kim S, Quinton TM. Platelet purinergic receptors. Curr Opin Pharmacol 2003;3(2): 175-180.
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329-1339.
14. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001;345(7):494-502.
15. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999;5(10):1199-1202.
16. Baurand A, Raboisson P, Freund M, Leon C, Cazenave JP, Bourguignon JJ et al. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 2001;412(3):213-221.
17. Leon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 2001;103(5):718-723.
18. Jagroop IA, Burnstock G, Mikhailidis DP. Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets. Platelets 2003;14(1):15-20.
19. Vial C, Rolf MG, Mahaut-Smith MP, Evans RJ. A study of P2X1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors. Br J Pharmacol 2002;135(2):363-372.
20. Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 2001;85(2):303-308.
21. Djaffar I, Vilette D, Bray PF, Rosa JP. Quantitative isolation of RNA from human platelets. Thromb Res 1991; 62(3):127-135.
22. Power CA, Clemetson JM, Clemetson KJ, Wells TN. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 1995;7(6):479-482.
23. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154(3):485-490.
24. Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA 1998;95(10):5556-5561.
25. Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM et al. Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J Cell Biol 1999;144(1):175-184.
26. Jagroop IA, Mikhailidis DP. Doxazosin, an alpha 1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Hum Hypertens 2001;15(3):203-207.
27. Jagroop IA, Mikhailidis DP. Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl. Platelets 2000;11(5):272-277.
28. Jagroop IA, Clatworthy I, Lewin J, Mikhailidis DP. Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy. Platelets 2000;11(1):28-32.
29. Jagroop IA, Barradas MA, Mikhailidis DP. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996;41(2):163-165.
30. Wang L, Karlsson L, Moses S, Hultgardh-Nilsson A, Andersson M, Borna C et al. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2002;40(6):841-853.
31. Jager E, Sinzinger H, Widhalm K, Kaliman J, Hofer R. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis]. Wien Klin Wochenschr 1982;94(16):421-425.
32. Sinzinger H, Fitscha P, Peskar BA. Platelet half-life, plasma thromboxane B2 and circulating endothelial-cells in peripheral vascular disease. Angiology 1986;37(2):112-118.
33. Sinzinger H, Kaliman J, Fitscha P, O'Grady J. Diminished platelet residence time on active human atherosclerotic lesions in vivo - evidence for an optimal dose of aspirin? Prostaglandins Leukot Essent Fatty Acids 1988;34(2):89-93.
34. Halperin JL. Evaluation of patients with peripheral vascular disease. Thromb Res 2002;106(6):V303-311.
35. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med 1998;3(3):241-245.
36. Cimminiello C. PAD. Epidemiology and pathophysiology. Thromb Res 2002;106(6):V295-301.
37. Frojmovic MM. Platelet aggregation in flow: differential roles for adhesive receptors and ligands. Am Heart J 1998; 135(5 Pt 2 Su):S119-131.
38. Goto S, Ikeda Y, Saldivar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998;101(2):479-486.
39. Matsagas M, Jagroop IA, Geroulakos G, Mikhailidis DP. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin Appl Thromb Hemost 2003;9(2):115-120.
40. Jagroop IA, Matsagas MI, Geroulakos G, Mikhailidis DP. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease. Platelets 2004;in press.
41. Vicari AM, Monzani ML, Pellegatta F, Ronchi P, Galli L, Folli F. Platelet calcium homeostasis is abnormal in patients with severe arteriosclerosis. Arterioscler Thromb 1994;14(9):1420-1424.
42. Reininger CB, Boeger CA, Steckmeier B, Spannagl M, Scweiberer L. Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results. Int Angiol 1999;18(2):163-170.
43. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88(6):787-800.
44. Barradas MA, Stansby G, Hamilton G, Mikhailidis DP. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease. In Vivo 1993;7(6A):543-548.
45. Barradas MA, Mikhailidis DP, Epemolu O, Jeremy JY, Fonseca V, Dandona P. Comparison of the platelet pro-aggregatory effect of conventional unfractionated heparins and a low molecular weight heparin fraction (CY 222). Br J Haematol 1987;67(4):451-457.